TRPS1 confers paclitaxel resistance in TNBC through dual activation of the PDE4D-cAMP-AKT pathway and microtubule destabilization.

Breast Cancer Res · 2026 · PMC12903692 · PMID 41559814

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

showed a trendp = 0.11not close (p > 0.1)

did not reach statistical significanceno p-value reported

In patients with triple-negative breast cancer (TNBC), high TRPS1 expression was significantly associated with worse overall survival (OS) (HR = 2.3, p = 0.037) and showed a trend toward poorer recurrence-free survival (RFS) (HR = 1.7, p = 0.11), although the latter did not reach statistical significance (Fig. 1 A).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.